中国再生医学(08158.HK):李柏聪将获任为公司秘书、授权代表及法律程序代理人
格隆汇9月13日丨中国再生医学(08158.HK)公布,叶永年将自2019年9月15日起辞任其所担任职位(i)公司秘书;(ii)联交所GEM证券上市规则第5.24条项下的公司授权代表;及(iii)根据公司条例(香港法例第622章)第16部代表公司在香港接收法律程序文件与通知的代理人,原因为彼将投入更多时间及精力于彼担任公司法律顾问的现时职务上。
董事会欣然宣布李柏聪将获委任为公司秘书、授权代表及法律程序代理人,有关委任自2019年9月16日起生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.